Renal cancer: Oxygen meets metabolism

Experimental Cell Research

Volumn 318, Issue 9, 2012, Pages 1057-1067

  Haase, Volker H ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glucose metabolism; Hypoxia inducible factor; Mitochondria; Oxygen; Renal cell cancer; VHL tumor suppressor

Indexed keywords

ACETYL COENZYME A; BEVACIZUMAB; CYCLIN D1; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; FUMARATE HYDRATASE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; I KAPPA B; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; OXYGEN; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; PYRUVATE DEHYDROGENASE KINASE; SORAFENIB; SUCCINATE DEHYDROGENASE; SUNITINIB; TEMSIROLIMUS; TIRAPAZAMINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; APOPTOSIS; BIOGENESIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; DNA REPAIR; DRUG EFFECT; DRUG MEGADOSE; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; GENOTYPE; GLUCOSE METABOLISM; GLYCOLYSIS; HETEROZYGOSITY; HUMAN; HYDROXYLATION; IN VITRO STUDY; KIDNEY CANCER; KIDNEY PROXIMAL TUBULE; LIPID STORAGE; NONHUMAN; OXYGEN CONSUMPTION; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION;

EID: 84859869957     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.02.026     Document Type: Review

References (112)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61:212-236.
2. Diaz J.I., Mora L.B., Hakam A. The Mainz classification of renal cell tumors. Cancer Control 1999, 6:571-579.
3. Mandriota S.J., Turner K.J., Davies D.R., Murray P.G., Morgan N.V., Sowter H.M., Wykoff C.C., Maher E.R., Harris A.L., Ratcliffe P.J., Maxwell P.H. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1:459-468.
4. Pavlovich C.P., Schmidt L.S. Searching for the hereditary causes of renal-cell carcinoma. Nat. Rev. Cancer 2004, 4:381-393.
5. Crino P.B., Nathanson K.L., Henske E.P. The tuberous sclerosis complex. N. Engl. J. Med. 2006, 355:1345-1356.
6. Vanharanta S., Buchta M., McWhinney S.R., Virta S.K., Peczkowska M., Morrison C.D., Lehtonen R., Januszewicz A., Jarvinen H., Juhola M., Mecklin J.P., Pukkala E., Herva R., Kiuru M., Nupponen N.N., Aaltonen L.A., Neumann H.P., Eng C. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 2004, 74:153-159.
7. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C., Myssiorek D., Bosch A., van der Mey A., Taschner P.E., Rubinstein W.S., Myers E.N., Richard C.W., Cornelisse C.J., Devilee P., Devlin B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287:848-851.
8. Morris M.R., Maina E., Morgan N.V., Gentle D., Astuti D., Moch H., Kishida T., Yao M., Schraml P., Richards F.M., Latif F., Maher E.R. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J. Clin. Pathol. 2004, 57:706-711.
9. Khoo S.K., Kahnoski K., Sugimura J., Petillo D., Chen J., Shockley K., Ludlow J., Knapp R., Giraud S., Richard S., Nordenskjold M., Teh B.T. Inactivation of BHD in sporadic renal tumors. Cancer Res. 2003, 63:4583-4587.
10. Lubensky I.A., Schmidt L., Zhuang Z., Weirich G., Pack S., Zambrano N., Walther M.M., Choyke P., Linehan W.M., Zbar B. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am. J. Pathol. 1999, 155:517-526.
11. Parry L., Maynard J.H., Patel A., Clifford S.C., Morrissey C., Maher E.R., Cheadle J.P., Sampson J.R. Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. Br. J. Cancer 2001, 85:1226-1230.
12. da Silva N.F., Gentle D., Hesson L.B., Morton D.G., Latif F., Maher E.R. Analysis of the Birt-Hogg-Dube (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer. J. Med. Genet. 2003, 40:820-824.
13. Nagy A., Zoubakov D., Stupar Z., Kovacs G. Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma. Int. J. Cancer 2004, 109:472-475.
14. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 2004, 22:4991-5004.
15. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 1999, 15:551-578.
16. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30:393-402.
17. Seizinger B.R., Rouleau G.A., Ozelius L.J., Lane A.H., Farmer G.E., Lamiell J.M., Haines J., Yuen J.W., Collins D., Majoor-Krakauer D., Bonner T., Mathew C., Rubenstein A., Halperin J., McConkie-Rosell A., Green J.S., Trofatter J.A., Ponder B.A., Eierman L., Bowmer M.I., Schimke R., Oostra B., Aronin N., Smith D.I., Drabkin H., Waziri M.H., Hobbs W.J., Martuza R.L., Conneally P.M., Hsia Y.E., Gusella J.F. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988, 332:268-269.
18. Latif F., Tory K., Gnarra J., Yao M., Duh F.M., Orcutt M.L., Stackhouse T., Kuzmin I., Modi W., Geil L., Schmidt L., Zhou F., Li H., Chen F., Glenn G., Choyke P., Walther M.M., Weng Y., Duan D.R., Dean M., Glavac D., Richards F.M., Crossey P.A., Ferguson-Smith M.A., Le Paslier D., Chumakov I., Cohen D., Chinault A.C., Maher E.R., Linehan W.M., Zbar B., Lerman M.I. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
19. Iliopoulos O., Levy A.P., Jiang C., Kaelin W.G., Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:10595-10599.
20. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [see comments]. Nature 1999, 399:271-275.
21. Lonser R.R., Glenn G.M., Walther M., Chew E.Y., Libutti S.K., Linehan W.M., Oldfield E.H. von Hippel-Lindau disease. Lancet 2003, 361:2059-2067.
22. Neumann H.P., Bender B.U. Genotype-phenotype correlations in von Hippel-Lindau disease. J. Intern. Med. 1998, 243:541-545.
23. Clifford S.C., Cockman M.E., Smallwood A.C., Mole D.R., Woodward E.R., Maxwell P.H., Ratcliffe P.J., Maher E.R. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 2001, 10:1029-1038.
24. Hoffman M.A., Ohh M., Yang H., Klco J.M., Ivan M., Kaelin W.G. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 2001, 10:1019-1027.
25. Kapitsinou P.P., Haase V.H. The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ. 2008, 15:650-659.
26. Wenger R.H., Stiehl D.P., Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci. STKE 2005, re12.
27. Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., Cao Y., Berkenstam A., Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001, 414:550-554.
28. Maynard M.A., Evans A.J., Shi W., Kim W.Y., Liu F.F., Ohh M. Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression. Cell Cycle 2007, 6:2810-2816.
29. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol. 2003, 23:9361-9374.
30. Kapitsinou P.P., Liu Q., Unger T.L., Rha J., Davidoff O., Keith B., Epstein J.A., Moores S.L., Erickson-Miller C.L., Haase V.H. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 2010, 116:3039-3048.
31. Haase V.H. Hypoxic regulation of erythropoiesis and iron metabolism. Am. J. Physiol. Renal Physiol. 2010, 299:F1-F13.
32. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004, 5:343-354.
33. Haase V.H. Hypoxia-inducible factors in the kidney. Am. J. Physiol. Renal Physiol. 2006, 291:F271-F281.
34. Stolze I.P., Tian Y.M., Appelhoff R.J., Turley H., Wykoff C.C., Gleadle J.M., Ratcliffe P.J. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes. J. Biol. Chem. 2004, 279:42719-42725.
35. Cario H., Schwarz K., Jorch N., Kyank U., Petrides P.E., Schneider D.T., Uhle R., Debatin K.M., Kohne E. Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica 2005, 90:19-24.
36. Russell R.C., Sufan R.I., Zhou B., Heir P., Bunda S., Sybingco S.S., Greer S.N., Roche O., Heathcote S.A., Chow V.W., Boba L.M., Richmond T.D., Hickey M.M., Barber D.L., Cheresh D.A., Simon M.C., Irwin M.S., Kim W.Y., Ohh M. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat. Med. 2011, 17:845-853.
37. Hickey M.M., Lam J.C., Bezman N.A., Rathmell W.K., Simon M.C. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. J. Clin. Invest. 2007, 117:3879-3889.
38. Ang S.O., Chen H., Hirota K., Gordeuk V.R., Jelinek J., Guan Y., Liu E., Sergueeva A.I., Miasnikova G.Y., Mole D., Maxwell P.H., Stockton D.W., Semenza G.L., Prchal J.T. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat. Genet. 2002, 32:614-621.
39. Smith T.G., Brooks J.T., Balanos G.M., Lappin T.R., Layton D.M., Leedham D.L., Liu C., Maxwell P.H., McMullin M.F., McNamara C.J., Percy M.J., Pugh C.W., Ratcliffe P.J., Talbot N.P., Treacy M., Robbins P.A. Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med. 2006, 3:e290.
40. Neumann H.P., Zbar B. Renal cysts, renal cancer and von Hippel-Lindau disease [editorial]. Kidney Int. 1997, 51:16-26.
41. Esteban M.A., Harten S.K., Tran M.G., Maxwell P.H. Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. J. Am. Soc. Nephrol. 2006, 17:1801-1806.
42. Yoder B.K. Role of primary cilia in the pathogenesis of polycystic kidney disease. J. Am. Soc. Nephrol. 2007, 18:1381-1388.
43. Schietke R., Hackenbeck T., Rosenberger C., Koesters R., Bachmann S., Eckardt K.U., Maxwell P., Wiesener M. The shift towards renal tubular HIF-2a expression causes cellular transformation, leading to fibrosis and cyst development. American Society of Nephrology Annual Meeting, J. Am. Soc. Nephrol., San Diego, CA 2009, TH-FC016.
44. Pollard P.J., Spencer-Dene B., Shukla D., Howarth K., Nye E., El-Bahrawy M., Deheragoda M., Joannou M., McDonald S., Martin A., Igarashi P., Varsani-Brown S., Rosewell I., Poulsom R., Maxwell P., Stamp G.W., Tomlinson I.P. Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 2007, 11:311-319.
45. Thoma C.R., Frew I.J., Hoerner C.R., Montani M., Moch H., Krek W. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat. Cell Biol. 2007, 9:588-595.
46. Schermer B., Ghenoiu C., Bartram M., Muller R.U., Kotsis F., Hohne M., Kuhn W., Rapka M., Nitschke R., Zentgraf H., Fliegauf M., Omran H., Walz G., Benzing T. The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth. J. Cell Biol. 2006, 175:547-554.
47. Lutz M.S., Burk R.D. Primary cilium formation requires von Hippel-Lindau gene function in renal-derived cells. Cancer Res. 2006, 66:6903-6907.
48. Dalgliesh G.L., Furge K., Greenman C., Chen L., Bignell G., Butler A., Davies H., Edkins S., Hardy C., Latimer C., Teague J., Andrews J., Barthorpe S., Beare D., Buck G., Campbell P.J., Forbes S., Jia M., Jones D., Knott H., Kok C.Y., Lau K.W., Leroy C., Lin M.L., McBride D.J., Maddison M., Maguire S., McLay K., Menzies A., Mironenko T., Mulderrig L., Mudie L., O'Meara S., Pleasance E., Rajasingham A., Shepherd R., Smith R., Stebbings L., Stephens P., Tang G., Tarpey P.S., Turrell K., Dykema K.J., Khoo S.K., Petillo D., Wondergem B., Anema J., Kahnoski R.J., Teh B.T., Stratton M.R., Futreal P.A. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
49. Krishnamachary B., Zagzag D., Nagasawa H., Rainey K., Okuyama H., Baek J.H., Semenza G.L. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 2006, 66:2725-2731.
50. Esteban M.A., Tran M.G., Harten S.K., Hill P., Castellanos M.C., Chandra A., Raval R., O'Brien S., Maxwell T.P.H. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 2006, 66:3567-3575.
51. Evans A.J., Russell R.C., Roche O., Burry T.N., Fish J.E., Chow V.W., Kim W.Y., Saravanan A., Maynard M.A., Gervais M.L., Sufan R.I., Roberts A.M., Wilson L.A., Betten M., Vandewalle C., Berx G., Marsden P.A., Irwin M.S., Teh B.T., Jewett M.A., Ohh M. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol. Cell. Biol. 2007, 27:157-169.
52. Calzada M.J., Esteban M.A., Feijoo-Cuaresma M., Castellanos M.C., Naranjo-Suarez S., Temes E., Mendez F., Yanez-Mo M., Ohh M., Landazuri M.O. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Cancer Res. 2006, 66:1553-1560.
53. Young A.P., Schlisio S., Minamishima Y.A., Zhang Q., Li L., Grisanzio C., Signoretti S., Kaelin W.G. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat. Cell Biol. 2008, 10:361-369.
54. Welford S.M., Dorie M.J., Li X., Haase V.H., Giaccia A.J. Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress. Mol. Cell. Biol. 2010, 30:4595-4603.
55. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000, 14:34-44.
56. Roe J.S., Kim H., Lee S.M., Kim S.T., Cho E.J., Youn H.D. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol. Cell 2006, 22:395-405.
57. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998, 392:405-408.
58. Yang H., Minamishima Y.A., Yan Q., Schlisio S., Ebert B.L., Zhang X., Zhang L., Kim W.Y., Olumi A.F., Kaelin W.G. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol. Cell 2007, 28:15-27.
59. Gordan J.D., Bertout J.A., Hu C.J., Diehl J.A., Simon M.C. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007, 11:335-347.
60. Koochekpour S., Jeffers M., Wang P.H., Gong C., Taylor G.A., Roessler L.M., Stearman R., Vasselli J.R., Stetler-Stevenson W.G., Kaelin W.G., Linehan W.M., Klausner R.D., Gnarra J.R., Vande Woude G.F. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol. Cell. Biol. 1999, 19:5902-5912.
61. Peruzzi B., Athauda G., Bottaro D.P. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14531-14536.
62. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
63. Wang Y., Roche O., Yan M.S., Finak G., Evans A.J., Metcalf J.L., Hast B.E., Hanna S.C., Wondergem B., Furge K.A., Irwin M.S., Kim W.Y., Teh B.T., Grinstein S., Park M., Marsden P.A., Ohh M. Regulation of endocytosis via the oxygen-sensing pathway. Nat. Med. 2009, 15:319-324.
64. Smith K., Gunaratnam L., Morley M., Franovic A., Mekhail K., Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res. 2005, 65:5221-5230.
65. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., Pugh C.W., Maxwell P.H., Harris A.L., Ratcliffe P.J. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 2005, 25:5675-5686.
66. Bindra R.S., Vasselli J.R., Stearman R., Linehan W.M., Klausner R.D. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 2002, 62:3014-3019.
67. Zatyka M., da Silva N.F., Clifford S.C., Morris M.R., Wiesener M.S., Eckardt K.U., Houlston R.S., Richards F.M., Latif F., Maher E.R. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 2002, 62:3803-3811.
68. Wykoff C.C., Sotiriou C., Cockman M.E., Ratcliffe P.J., Maxwell P., Liu E., Harris A.L. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br. J. Cancer 2004, 90:1235-1243.
69. Kurban G., Duplan E., Ramlal N., Hudon V., Sado Y., Ninomiya Y., Pause A. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2. Oncogene 2008, 27:1004-1012.
70. Kurban G., Hudon V., Duplan E., Ohh M., Pause A. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res. 2006, 66:1313-1319.
71. Ohh M., Yauch R.L., Lonergan K.M., Whaley J.M., Stemmer-Rachamimov A.O., Louis D.N., Gavin B.J., Kley N., Kaelin W.G., Iliopoulos O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1998, 1:959-968.
72. Davidowitz E.J., Schoenfeld A.R., Burk R.D. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol. Cell. Biol. 2001, 21:865-874.
73. Bishop T., Lau K.W., Epstein A.C., Kim S.K., Jiang M., O'Rourke D., Pugh C.W., Gleadle J.M., Taylor M.S., Hodgkin J., Ratcliffe P.J. Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans. PLoS Biol. 2004, 2:e289.
74. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., Czernin J., Sawyers C.L. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 2006, 12:122-127.
75. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425:307-311.
76. Turner K.J., Moore J.W., Jones A., Taylor C.F., Cuthbert-Heavens D., Han C., Leek R.D., Gatter K.C., Maxwell P.H., Ratcliffe P.J., Cranston D., Harris A.L. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res. 2002, 62:2957-2961.
77. Gordan J.D., Lal P., Dondeti V.R., Letrero R., Parekh K.N., Oquendo C.E., Greenberg R.A., Flaherty K.T., Rathmell W.K., Keith B., Simon M.C., Nathanson K.L. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008, 14:435-446.
78. Kondo K., Klco J.M., Nakamura E., Lechpammer M., Kaelin W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002, 1:237-246.
79. Maranchi J.K., Vasselli J.R., Riss J., Bonifacio J.S., Linehan W.M., Klausner R.D. The contribution of VHL substrate binding and HIF-1α to the phenotype of vhl loss in renal cell carcinoma. Cancer Cell 2002, 1:247-253.
80. Zimmer M., Doucette D., Siddiqui N., Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol. Cancer Res. 2004, 2:89-95.
81. Kondo K., Kim W.Y., Lechpammer M., Kaelin W.G. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003, 1:E83.
82. Keith B., Johnson R.S., Simon M.C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2011, 12:9-22.
83. Rankin E.B., Rha J., Unger T.L., Wu C.H., Shutt H.P., Johnson R.S., Simon M.C., Keith B., Haase V.H. Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 2008, 27:5354-5358.
84. Hergovich A., Lisztwan J., Barry R., Ballschmieter P., Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat. Cell Biol. 2003, 5:64-70.
85. Xu J., Li H., Wang B., Xu Y., Yang J., Zhang X., Harten S.K., Shukla D., Maxwell P.H., Pei D., Esteban M.A. VHL inactivation induces HEF1 and Aurora kinase A. J. Am. Soc. Nephrol. 2010, 21:2041-2046.
86. Frew I.J., Thoma C.R., Georgiev S., Minola A., Hitz M., Montani M., Moch H., Krek W. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J. 2008, 27:1747-1757.
87. Frew I.J., Minola A., Georgiev S., Hitz M., Moch H., Richard S., Vortmeyer A.O., Krek W. Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. Mol. Cell. Biol. 2008, 28:4536-4548.
88. Chitalia V.C., Foy R.L., Bachschmid M.M., Zeng L., Panchenko M.V., Zhou M.I., Bharti A., Seldin D.C., Lecker S.H., Dominguez I., Cohen H.T. Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat. Cell Biol. 2008, 10:1208-1216.
89. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
90. Weinberg F., Chandel N.S. Mitochondrial metabolism and cancer. Ann. N. Y. Acad. Sci. 2009, 1177:66-73.
91. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
92. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., Abraham R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2002, 22:7004-7014.
93. Seagroves T.N., Ryan H.E., Lu H., Wouters B.G., Knapp M., Thibault P., Laderoute K., Johnson R.S. Transcription factor hif-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol. Cell. Biol. 2001, 21:3436-3444.
94. Papandreou I., Cairns R.A., Fontana L., Lim A.L., Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006, 3:187-197.
95. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-185.
96. Luo W., Hu H., Chang R., Zhong J., Knabel M., O'Meally R., Cole R.N., Pandey A., Semenza G.L. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011, 145:732-744.
97. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
98. Vander Heiden M.G., Locasale J.W., Swanson K.D., Sharfi H., Heffron G.J., Amador-Noguez D., Christofk H.R., Wagner G., Rabinowitz J.D., Asara J.M., Cantley L.C. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010, 329:1492-1499.
99. Parks S.K., Chiche J., Pouyssegur J. pH control mechanisms of tumor survival and growth. J. Cell. Physiol. 2011, 226:299-308.
100. Zhang H., Gao P., Fukuda R., Kumar G., Krishnamachary B., Zeller K.I., Dang C.V., Semenza G.L. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007, 11:407-420.
101. Fukuda R., Zhang H., Kim J.W., Shimoda L., Dang C.V., Semenza G.L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007, 129:111-122.
102. Zhang H., Bosch-Marce M., Shimoda L.A., Tan Y.S., Baek J.H., Wesley J.B., Gonzalez F.J., Semenza G.L. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 2008, 283:10892-10903.
103. Rankin E.B., Rha J., Selak M.A., Unger T.L., Keith B., Liu Q., Haase V.H. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol. Cell. Biol. 2009, 29:4527-4538.
104. Krishnan J., Suter M., Windak R., Krebs T., Felley A., Montessuit C., Tokarska-Schlattner M., Aasum E., Bogdanova A., Perriard E., Perriard J.C., Larsen T., Pedrazzini T., Krek W. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab. 2009, 9:512-524.
105. Pescador N., Villar D., Cifuentes D., Garcia-Rocha M., Ortiz-Barahona A., Vazquez S., Ordonez A., Cuevas Y., Saez-Morales D., Garcia-Bermejo M.L., Landazuri M.O., Guinovart J., del Peso L. Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase 1. PLoS One 2010, 5:e9644.
106. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349:427-434.
107. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356:115-124.
108. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C.H., Salman P., Gladkov O.A., Kavina A., Zarba J.J., Chen M., McCann L., Pandite L., Roychowdhury D.F., Hawkins R.E. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 2010, 28:1061-1068.
109. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A.A., Rolland F., Demkow T., Hutson T.E., Gore M., Freeman S., Schwartz B., Shan M., Simantov R., Bukowski R.M. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356:125-134.
110. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I.G., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R.J. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356:2271-2281.
111. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grunwald V., Thompson J.A., Figlin R.A., Hollaender N., Urbanowitz G., Berg W.J., Kay A., Lebwohl D., Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
112. Holley J.L. Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin. J. Am. Soc. Nephrol. 2007, 2:604-610.